Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class Iop-lowering Drug Candidate for Glaucoma

DEDHAM, Mass.--(BUSINESS WIRE)-- #EVP--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. Co-led by Canaan and New Leaf Venture Partners, the financing also included new participation from funds managed by abrdn Inc., as well as existing investors Mayo Clinic Ventures and Correlation Ventures. Proceeds from the financing will support the continued clini